Bone marrow disease
Education on Bone marrow disease and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Bone marrow disease and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Bone marrow disease?
Bone marrow disease is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Hematologic conditions involve blood cells and bone marrow. The patent discusses marrow health and neutrophil balance.
What Mark Egly's patent discusses
Bone marrow is a soft fatty tissue found inside the central spongy part of bones throughout the skeleton and is the body's primary producer of white blood cells, red blood cells, and platelets. There are five different types of white blood cells: lymphocytes, neutrophils, eosinophils, basophils, and monocytes. Each type of white blood cell plays a different role in protecting the body from infection. The chemotherapy and radiation that is typical in cancer treatment causes severe damage to bone marrow; thus, the body's normal production of white blood cells, red blood cells, and platelets is adversely affected. A method of preventing cancer is provided such that the use of chemotherapy and radiation is reduced or eliminated and damage to bone marrow is reduced or eliminated. Neutrophils, basophils, and eosinophils kill and digest bacteria. Neutrophils migrate to the site of an infection in the body to begin killing the invading microbes. However, neutrophils release enzymes such as Neutrophil Elastase ("NE"), Cathepsin G ("CG"), Proteinase 3, and others that target and destroy thrombospondin 1 ("tsp1" or "thbs1"), a protein that acts as a natural inhibitor of neovascularization an…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Bone marrow disease, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Bone marrow disease, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: